Time filter

Source Type

Patent
Otsuka Pharmaceutical Factory Inc. | Date: 2016-11-23

Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.


Patent
Otsuka Pharmaceutical Factory Inc. | Date: 2016-08-22

Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension.


Patent
Otsuka Pharmaceutical Factory Inc. | Date: 2016-10-14

An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or of a salt thereof, and a process for producing the same.


Patent
Osaka University and Otsuka Pharmaceutical Factory Inc. | Date: 2016-12-02

An object of the present invention is to provide a biomarker that can be used as a precise diagnostic marker for MetS or arteriosclerosis risk. The present invention provides a C1q-adiponectin complex comprising naturally occurring adiponectin and C1q.


Patent
Otsuka Pharmaceutical Factory Inc. | Date: 2017-03-01

A major object of the present invention is to provide an effective means for promoting polyamine synthesis in an organism (in particular, in humans).


Patent
Otsuka Pharmaceutical Factory Inc. | Date: 2016-04-20

Provided is a method and apparatus for manufacturing nucleated tablets in each of which a nucleus is positioned in a precise manner. In the tablet manufacturing machine (1), granules are charged in a mortar and then compressed by pestles while the mortar and the pestles travel along a cyclic path extending from a point and then back to the point. The path has a substantially straight path portion where the mortar and the pestles travel substantially straightly.


Patent
Mie University and Otsuka Pharmaceutical Factory Inc. | Date: 2016-01-19

Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.


Patent
Otsuka Pharmaceutical Factory Inc. | Date: 2016-09-15

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.


Patent
Toyo Sugar Refining Co. and Otsuka Pharmaceutical Factory Inc. | Date: 2016-09-01

An object of the present invention is to provide a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder having an excellent suppressive effect on a keratoconjunctival disorder. The invention relates to a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder containing glucosylglycerol as an active ingredient, use of glucosylglycerol for the manufacture of a pharmaceutical for protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder and a method of protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder comprising administering glucosylglycerol.


Patent
GW Pharma Ltd and Otsuka Pharmaceutical Factory Inc. | Date: 2016-11-23

The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.

Loading Otsuka Pharmaceutical Factory Inc. collaborators
Loading Otsuka Pharmaceutical Factory Inc. collaborators